United Kingdom· GB-APID-37234911000001107
Brinavess 500mg/25ml concentrate for solution for infusion vials
A vernakalant product containing vernakalant, registered in United Kingdom by Advanz Pharma. The same ATC class is registered in 12 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Vernakalant is registered in 12 of 19 countries.
Countries holding a registration under ATC C01BG11 (vernakalant), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 7 of them publish a price we can compare per daily dose
Vernakalant · ATC C01BG11
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Vernakalant
- Manufacturer
- Advanz Pharma
- Country
- United Kingdom (GB)
- ATC code
- C01BG11
- ATC class
- Vernakalant
- Defined daily dose
- 0.2 g, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin07640160350053
- gtin05021691003601
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Vernakalant in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBRINAVESSADVANZ PHARMA Limited, Dublin
- BelgiumBrinavess 20 mg/mlAdvanz Pharma
- SpainBRINAVESS 20 mg/ml, CONCENTRADO PARA SOLUCION PARA PERFUSIONAdvanz Pharma Limited
- FinlandBRINAVESSAdvanz Pharma Limited
- IrelandBRINAVESS 20 mg/ml concentrate for solution for infusionCorrevio
- IcelandBrinavessADVANZ PHARMA Limited
- NetherlandsBrinavess 20 mg / ml, concentraat voor oplossing voor infusieAdvanz Pharma Limited
- PolandBrinavessCorrevio
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Brinavess
- Liechtenstein · Brinavess
- Norway · Brinavess
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5d053460-e24d-4179-a661-0fb083a7d3f9 GET /v1/drugs/5d053460-e24d-4179-a661-0fb083a7d3f9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "37234911000001107",
"desc": "Brinavess 500mg/25ml concentrate for solution for infusion vials (Advanz Pharma)",
"form": "Solution for infusion",
"vpid": "37236311000001100",
"source": "dmd",
"vtm_id": "37238511000001107",
"strength": "20 mg",
"substance": "Vernakalant",
"ingredient": "Vernakalant hydrochloride",
"supplier_code": "24129411000001106"
}See everything about vernakalant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.